US-based global medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Friday that it has received approval from Pharmaceuticals and Medical Device Agency (PMDA) in Japan for the FARAPULSE Pulsed Field Ablation (PFA) System.
The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation (AF), and is a novel alternative to standard-of-care thermal ablation treatment.
Boston Scientific is expected to commence the OPTION-A clinical trial in Japan, China, Taiwan and Hong Kong in early 2025. The trial is to study the safety and efficacy of concomitant procedures utilising the FARAPULSE PFA System for cardiac ablation and the WATCHMAN FLX Pro Left Atrial Appendage Closure Device.
The company plans to launch the FARAPULSE PFA System in Japan in the coming weeks, following reimbursement approval.
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Genetesis' CardioFlux Magnetocardiograph receives Health Canada approval
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
Bayer launches Phase II study for chronic kidney disease treatment
Johnson & Johnson agrees acquisition of V-Wave
AbCellera expands collaboration with Lilly
AstraZeneca's Calquence combo improves 1L CLL progression-free survival
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients